Table 1.
Baseline characteristics of the study population
| TP53 mutant (n = 30) | TP53 wild type (n = 73) | |
|---|---|---|
| Median age (range), y** | 68 (47-86) | 76 (37-96) |
| Male | 15 (50) | 46 (63) |
| Female | 15 (50) | 27 (37) |
| WHO subtype | ||
| MDS | 12 (40) | 47 (64) |
| sAML** | 18 (60) | 19 (26) |
| CMML | 0 | 7 (10) |
| Median hemoglobin (range), g/dL | 8.6 (6.6-19) | 9 (6.7-15.3) |
| Median platelets (range), × 109/L** | 58 (7-208) | 95 (3-1093) |
| Median ANC (range) | 1.52 (0.2-13.77) | 2 (0.08-20.02) |
| Median BM blast % (range)** | 24.5 (1-70) | 10 (0-80) |
| IPSS-R (< 30% blasts) | ||
| Very low | 1 (5) | 6 (10) |
| Low | 19 (30) | |
| Intermediate | 14 (22) | |
| High | 3 (14) | 14 (22) |
| Very high | 17 (81) | 10 (16) |
| Median TP53 VAF (range), % | 52 (6-94) | N/A |
| Median mutations, n* | 1 (1-3) | 2 (0-7) |
| Time of flow assessment | ||
| Prior to first line treatment | 17 (56) | 37 (51) |
| HMA therapy | ||
| HMA naive | 16 (53) | 45 (62) |
| HMA relapse/refractory | 11 (37) | 20 (27) |
| On HMA | 3 (10) | 8 (11) |
| Allo-HSCT | 8 (27) | 19 (26) |
| Median OS, mo**** | 5.5 | 19.9 |
| Median follow-up, mo | 41.9 mo | 39.4 |
Total population, N = 103. Unless stated otherwise, data are expressed as number of patients in the subgroup (percentage of subgroup).
ANC, absolute neutrophil count; N/A, not applicable.
*
P < .05; **P < .01; ****P < .0001.